Multicentre, Prospective Randomized Open Label, Blinded-endpoint (PROBE) Controlled Trial of Early Anticoagulation With Rivaroxaban Versus Standard of Care in Determining Safety at 365 Days in Symptomatic Cerebral Venous Thrombosis
Not yet recruiting
Phase of Trial: Phase II
Latest Information Update: 16 Oct 2018
At a glance
- Drugs Rivaroxaban (Primary) ; Low molecular weight heparin
- Indications Venous thrombosis
- Focus Adverse reactions
- Acronyms SECRET
- 09 Oct 2018 Planned initiation date changed from 1 Sep 2018 to 31 Oct 2018.
- 01 Aug 2018 Planned number of patients changed from 384 to 380.
- 01 Aug 2018 Planned End Date changed from 1 Jun 2020 to 1 Dec 2020.